Members
Meet our new members
Meet the newest members in our cluster.
News and press releases
EUAll you need to know about EU funding
A well-planned soft funding strategy can unleash a company's potential and help bring its idea to market faster.
CollaborationSamarbeid for bedre læring og rekruttering
Samarbeidsdagene på Ullern videregående skole ble holdt for tiende år på rad.
AwardFinalists for the innovation prize
Three finalists are shortlisted for the Norwegian Cancer Society Innovation Prize.
- Members
Meet our new members
Meet the members who joined our cluster so far this year.
EventCollaborationGathering in Berlin for cancer innovation
Under the banner “Catalyzing Collaborations for Global Impact,” the CONNECT Nordics symposium challenged European actors to move beyond borders and build the partnerships needed to drive the next generation of cancer innovation.
Subscribe to our newsletter
Get monthly news updates and invitations to events from our oncology cluster.
EventAdvancing cell therapy manufacturing
The Cell Therapy Innovation Symposium gathered scientists, process developers, and industry leaders from across Europe to explore the latest advances and challenges in immune cell therapy manufacturing.
EventLung cancer: Path to early detection
Oslo Cancer Cluster brought together leading experts from across the Nordics, the UK, and the US for a full-day symposium focused on lung cancer screening.
ResearchDeveloping a new CAR-T Therapy
Scientists are developing new CAR-T cell therapy in their laboratories located at Oslo Cancer Cluster Incubator.
EUBringing Europe together to tackle Lynch syndrome
The PREDI-LYNCH project kicks off in Heidelberg.
CollaborationCelebrating 15 years of collaboration
The partnership between Oslo Cancer Cluster and Ullern Upper Secondary School marks its 15th anniversary in 2025. The milestone was celebrated at Oslo Cancer Cluster Innovation Park on 15 September with a lively programme.
Start-up€2.2 million Eurostars Project
AdjuTec Pharma has been awarded a €2.2 million Eurostars grant together with international partners. The funding will support the development of new drug combinations for patients suffering from severe lung infections caused by multidrug-resistant bacteria.
